<DOC>
	<DOCNO>NCT01522378</DOCNO>
	<brief_summary>Congestive heart failure ( CHF ) affect nearly 5 million Americans claim 300,000 life annually . A primary pathophysiologic mechanism deadly syndrome abnormally enhance sympathetic nervous system result profound peripheral vasoconstriction , attenuate cardiovascular reflex , high susceptibility ventricular arrhythmia , sudden cardiac death . The reduction mortality morbidity CHF pharmacologic neurohumoral antagonist beta-receptor inhibitor angiotensin II-converting enzyme ( ACE ) inhibitor teach u regulation impair neurohumoral axis important improve clinical outcome . In addition , emerge nonpharmacologic approach , cardiac resynchronization therapy ( CRT ) , show promise improve symptom quality life patient New York Heart Association ( NYHA ) functional class III IV intraventricular conduction delay . However , despite significant advance CHF treatment past two decade , gap remain clinical outcome mechanism protective effect modern therapy . CHF associate increased concentration circulate norepinephrine ( NE ) , down-regulation adrenergic nerve terminal , abnormal NE reuptake . The suppression cardiac sympathetic nerve ending could reverse CRT , novel anti-heart failure therapy , rebalance cardiac sympathetic activity , improve cardiac function patient heart failure .</brief_summary>
	<brief_title>Cardiac Resynchronization Iodine Meta-Iodobenzylguanidine ( MIBG ) Imaging</brief_title>
	<detailed_description>The Specific Aim # 1 study ass , 123iodine metaiodobenzylguanidine ( 123I-MIBG imaging ) , whether CRT rebalances improve integrity function sympathetic nerve terminal fail myocardium . The study test hypothesis resynchronization biventricular contractility attenuate excessive sympathetic drive , improve autonomic function cardiac performance . The Specific Aim # 2 study determine relationship 123I-MIBG labeling sympathetic activity physiological measure cardiopulmonary autonomic function . This aim test hypothesis impair cardiac sympathetic activity , determine 123I-MIBG imaging associate poor submaximal exercise gas exchange ( high ventilation - CO2 slope , low end tidal CO2 , reduce oxygen pulse rapid frequency response ) well reduce heart rate power spectral frequency , blunt response positional change delay heart rate recovery .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Inclusion criterion : Indications BivICD implantation 1 . Chronic moderate severe CHF ( NYHA class II IV ) 2 . Left ventricular ejection fraction ( LVEF ) 35 % less 3 . QRS duration 120 m 4 . On optimized antiheart failure medical regimen 5 . Meet one follow indication ICD Survivors cardiac arrest due ventricular fibrillation ( VF ) ventricular tachycardia ( VT ) spontaneous sustain VT Nonsustained VT coronary disease , prior myocardial infarction , LVEF 35 % less , inducible VF sustain VT electrophysiologic study LVEF 30 % less severe coronary artery disease Exclusion criterion : 1 . Patient condition unstable 2 . Patient unable give inform consent 3 . Not feasible patient follow Mayo Clinic 4 . Female pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cardiac resynchronization therapy</keyword>
</DOC>